GlaxoSmithKline and Human Genome Sciences announce full presentation at ACR of positive phase 3 study results for BENLYSTA in systemic lupus erythematosus

BENLYSTA (belimumab) significantly reduced SLE disease activity, disease flare rates and fatigue; significantly delayed time-to-first SLE disease flare; reduced prednisone use and improved health-related patient quality of life in the BLISS-52 study